Ultragenyx Pharmaceutical RARE Total debt
Discontinued — last reported Q4 '25
Total debt at other companies
Other financials
Where this comes from
Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $36M.
The official record: Ultragenyx Pharmaceutical’s 10-K, filed February 18, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's total debt?
- Ultragenyx Pharmaceutical (RARE) reported total debt of $36M in Q4 2025.
- How has Ultragenyx Pharmaceutical's total debt changed year-over-year?
- Ultragenyx Pharmaceutical's total debt decreased by 10.8% year-over-year, from $40.34M to $36M.
- What is the long-term trend for Ultragenyx Pharmaceutical's total debt?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's total debt has grown at a -5.7% compound annual growth rate (CAGR), from $48.23M to $36M.
- What does total debt mean?
- Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.